Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 5Phase 2 5Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 2

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Breast Neoplasms 239Carcinoma, Non-Small-Cell Lung 237Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 136Colorectal Neoplasms 127Leukemia, Myeloid, Acute 123Lung Neoplasms 110Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 77Ovarian Neoplasms 72Sarcoma 71Carcinoma, Renal Cell 66Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 57Lymphoma, Non-Hodgkin 56Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 54Hematologic Neoplasms 53Endometrial Neoplasms 53Urinary Bladder Neoplasms 51Small Cell Lung Carcinoma 50

Interventions

daratumumab 1belantamab mafodotin 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × 90 days × Clear all
NCT05951049 2026-05-06

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Attralus, Inc.

Phase 2 Active not recruiting
120 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07524634 2026-04-24

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting
64 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06649695 2026-04-21

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

European Myeloma Network B.V.

Phase 2 Recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Mayo Clinic

Phase 2 Recruiting
96 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡